PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

Original languageEnglish (US)
Pages (from-to)139-148
Number of pages10
JournalFuture Cardiology
Volume12
Issue number2
DOIs
Publication statusPublished - Mar 1 2016

    Fingerprint

Keywords

  • alirocumab
  • evolocumab
  • LDL
  • monoclonal antibodies
  • PCSK9 inhibitors
  • statin intolerance

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., ... Martin, S. S. (2016). PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab. Future Cardiology, 12(2), 139-148. https://doi.org/10.2217/fca.15.89